tiprankstipranks
Blurbs

Akebia Therapeutics (AKBA) Received its Third Buy in a Row

After Needham and H.C. Wainwright gave Akebia Therapeutics (NASDAQ: AKBA) a Buy rating last month, the company received another Buy, this time from Mizuho Securities. Analyst Mara Goldstein maintained a Buy rating on Akebia Therapeutics yesterday and set a price target of $6.00. The company’s shares closed last Tuesday at $2.15.

According to TipRanks.com, Goldstein is a 4-star analyst with an average return of 7.2% and a 36.5% success rate. Goldstein covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics, Neoleukin Therapeutics, and Autolus Therapeutics.

Currently, the analyst consensus on Akebia Therapeutics is a Strong Buy with an average price target of $7.67, a 237.9% upside from current levels. In a report issued on February 22, Piper Sandler also maintained a Buy rating on the stock with a $8.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Akebia Therapeutics’ market cap is currently $377.9M and has a P/E ratio of -1.13.

Based on the recent corporate insider activity of 18 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of AKBA in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney disease. The firm also involves in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vadadustat. The company was founded by Joseph H. Gardner, John M. Rice, Michael E. Pape, Josh P. Fairbank, and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA.

Read More on AKBA:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed